Skip to content

Share
Share

Technology Opportunities

Monash University is recognised for its success in developing new products and services with our partners. We are leaders in commercialising inventions and developing Intellectual Property Portfolios that maximise impact for your business and together work to create a better world.  We  license  technologies  and  form spinout companies , facilitating the process through seed funding.

Our researchers have the know-how and experience to develop ground-breaking innovations, technologies and methods. Browse some of our available technologies below and Contact Us if you are interested in a particular area that may or may not be listed here.

Email innovation@monash.edu for more information.

↑ Back to top

Physical Sciences / Engineering / ICT


diagram

Chordalysis: a new tool for analysing big data
(PDF, 0.07 MB)

A method to discover the structure of big data. The software tool is able to discover multi-way interactions between variables; can be scaled-up to address hundreds of variables on a standard desktop computer.


diagram

Drying-free ceramic casting method
(PDF, 0.08 MB)

Monash researchers led by Professor Huanting Wang have developed a method for shape forming of a ceramic green body that eliminates the conventional drying step.


diagram

Gel-form graphene
(PDF, 0.07 MB)

A novel method for converting natural graphite into gel-film form graphene-based material. Each graphene sheet is physically separated by an entrapped liquid or through corrugation, whilst maintaining reasonable mechanical strength.


diagram

Graphene oxide reinforced concrete
(PDF, 0.07 MB)

Monash researchers, led by Dr Wenhui Duan, have discovered a novel method for reinforcing concrete construction materials. The cementitious matrix has enhanced strength and durability through the incorporation of graphene oxide (GO).


Hollow recycled polymer blocks

Hollow recycled polymer blocks for human habitation
(PDF, 0.16 MB)

Innovative hollow, fillable building blocks which can be stacked to form stable structures. The blocks can be manufactured from recycled plastics and are re-usable.


diagram

New generation of X-ray Computed Tomography
(PDF, 0.44 MB)

Low Dose Radiation up to 100x lower than current Computed Tomography (CT). Monash Science are developing novel algorithms for next generation CT Scanners with greatly reduced radiation risk to patients.


diagram

New polymer energy absorption fibres for anti-penetrationy
(PDF, 0.44 MB)

New polymers that can be formulated into fibres with properties similar to spider silk and carbon nanotubes.


diagram

Noncovalent magnetic purification of metals using graphene oxide
(PDF, 0.38 MB)

A new system to improve the purification of metals and ionic material from water and other aqueous solutions by magnetic separation using graphene oxide (GO). Both the metals and the GO adsorbant material can be recycled.


diagram

Pelletized adsorbents and their production for CO2 capture and other applications
(PDF, 0.38 MB)

A new method to produce compression amine (PEI) type pelletized sorbents without additional binder. The pellets demonstrate a high capacity for CO2 capture, with highly selective 'molecular basket' sorbents.


diagram

Revolutionary chromatography method for protein and antibody purification
(PDF, 0.18 MB)

New ligand-matrix conjugates and methods that improve the separation and purification of proteins and monoclonal antibodies by chromatography. The method offers several benefits including unique binding site selectivity.


↑ Back to top

Life Sciences


diagram

Modular high content zebrafish drug discovery platform
(PDF, 0.18 MB)

An adaptable modular, high-throughput drug screening technology. The technology can be applied to numerous disease models and is currently being utilised in high throughput/content screens in drug discovery for muscular dystrophy.


diagram

Stimuli responsive drug delivery systems based on lipid nanostructures
(PDF, 0.35 MB)

Drug delivery systems that respond to a range of stimuli to release the drug 'on demand'. This has potential to replace multiple injection treatment regimens with more convenient and patient friendly non-invasive release.



diagram

Enhanced CD8+ CTL formation for Adoptive Cell Therapies
(PDF, 0.31 MB)

Compositions and methods that direct ex vivo cultured T cells to a Cytotoxic T lymphocyte (CTL) fate in a T helper cell independent manner. This method provides an efficient production of activated CD8+ T cells for adoptive T cell therapy (ACT).


diagram

Immuno-oncology monoclonal antibody
(PDF, 0.16 MB)

A novel and highly differentiated immunomodulatory monoclonal antibody to the human Interleukin-21 cytokine that acts as a 'superagonist'. This antibody enhances endogenous IL-21 signalling and could be used to harness patient immune systems.


diagram

Oncology: Tumour specific monoclonal Antibody
(PDF, 0.22 MB)

Novel monoclonal antibodies that bind a unique epitope on a cancer-associated form of the ADAM10 metalloprotease. The lead mAb binds an active conformation of ADAM10 to inhibit its enzymatic function and is potentially useful as a 'cancer specific' single agent, ADC vector and/or combination therapy  medicament.


diagram

Prostate cancer: New target for identifying and treating aggressive disease
(PDF, 0.09 MB)

Analysis of a key androgen signalling independent pathway in prostate cancer (PCa) progression and a crucial extracellular target. This pathway could inhibit a highly aggressive sub-group of disease if agonized, including castration-resistant disease.


digram

Stabilised peptides to Grb7 – A new oncology drug class/target
(PDF, 0.69 MB)

Stabilised peptides that specifically inhibit the activity of the Grb7 adaptor protein as a potential new target for oncology drugs for tumours driven by epidermal growth factor receptor (EGFR) and/or ephrin receptors.


↑ Back to top

Infection


diagram

Anti-infectives targeting Gram-negative 'superbugs'
(PDF, 0.56 MB)

New generation polymixins that target multidrug-resistant Gram-negative bacteria. These novel lipopeptide antibiotics have demonstrated superior in vivo efficacy and toxicity over the currently used polymixin antibiotics.


diagram

Anti-viral drug discovery platform
(PDF, 0.15 MB)

A novel high throughput assay focused on specifically inhibiting nuclear import of viral proteins. The assay has identified a number of anti-viral drug candidates that target an evolutionarily conserved mechanism of action across numerous viral species.


diagram

Chronic viral infection monoclonal antibody
(PDF, 0.13 MB)

A novel and highly differentiated immunomodulatory monoclonal antibody to the human Interleukin-21 cytokine that acts as a 'superagonist'. This antibody enhances endogenous IL-21 signalling and could be used to harness patient immune systems.


diagram

Lymph-directing prodrugs offering enhanced oral bioavailability and immune cell targeting
(PDF, 0.22 MB)

A novel lymph-directing prodrug technology based on natural triglyceride which promotes transport to the intestinal lymph, offering the potential of enhanced oral bioavailability by avoiding first pass hepatic metabolism.


diagram

MicroCube technology vaccine platform
(PDF, 0.81 MB)

The MicroCube is uniquely suited to the delivery of vaccines in a safe, stable and effective way. MicroCubes are protein-based vaccines that can accommodate various antigens and can elicit strong T-cell responses.


diagram

Novel Kv1.3 inhibitory peptides for treating autoimmune disease
(PDF, 0.11 MB)

Novel peptides that are highly potent and selective inhibitors of the Kv1.3 potassium channel. Clinical support for inhibition of the target with unmodified peptides was achieved in a Phase 1b study in patients with active plaque psoriasis.


↑ Back to top

Inflammation/Fibrosis


diagram

Angiotensin AT2 receptor-selective agonists
(PDF, 0.24 MB)

A range of exquisitely selective ligands that stimulate AT2 receptors (but not AT1) for the development of anti-fibrotic medications. Lead compounds completely reverse elevated cardiac fibrosis in preclinical models.


diagram

Anti-fibrotic drug development
(PDF, 0.48 MB)

Unique classes of small molecules that inhibit site specific acetylation of SMAD3 to prevent its fibrosis-promoting activity in response to TGF-β 1 signalling. The molecules do not inhibit other transcriptional functions.


diagram

Fibrosis laboratory – Discovery/pre-clinical testing services
(PDF, 0.1 MB)

Culture systems and in vivo models across various major fibrosis indications (cardiovascular, renal and lung). The systems and models can examine anti-fibrotic efficacy and mechanisms of various emerging therapies.


diagram

Immuno-oncology: Novel 'Cytokine Release Syndrome' therapeutic
(PDF, 0.2 MB)

Novel target residues for point mutations in a key cytokine. These mutations alter the cytokine's biologic properties and promote an unexpected and potent anti-inflammatory response in vitro, ex vivo (human PBMCs) and in vivo (rodent).


diagram

New target for development of anti-fibrotic drugs
(PDF, 0.29 MB)

A new target for the development of anti-fibrotic medications that, when inhibited via small molecule reagents in aged mice, completely reverses age-induced cardiac fibrosis. The target is readily 'druggable' by small molecules.


diagram

Optimised inhibitors of a novel target for treatment of fibrosis
(PDF, 0.37 MB)

A new enzymatic target for treatment of fibrosis and a series of highly potent drug-like inhibitors of the target. The inhibitors have shown 100 times potency in functional assays of fibrosis (inhibiting collagen secretion) than leading clinical compounds.


↑ Back to top

Metabolic Disease


diagram

New target for Type 2 Diabetes Mellitus
(PDF, 0.15 MB)

An orphan cytokine that increases insulin levels and improves glucose clearance in type 2 diabetic (T2D) mouse models. This target operates in a manner similar to GLP-1 agonists and provides a new target(s), and potentially new mechanism(s).


↑ Back to top

Neuroscience


diagram

GAD65 – A new target for anxiolytics
(PDF, 0.29 MB)

GAD65 is a new anxiolytic drug target. The team has identified the structural mechanism that converts GAD65 from an inactive to active state. This knowledge could form the basis of a development program for creating novel, targeted therapies.


diagram

Ischemic stroke: New targets from a clinically relevant primate model
(PDF, 0.39 MB)

A non-human primate (NHP) model that accurately replicates the stages of disease progression in human ischemic stroke. Using this model, the team has identified new receptor tyrosine kinase based targets.


↑ Back to top

Orphan/Rare Diseases


diagram

Anti-inflammatory agent for rare/ultra-rare orphan skin indications
(PDF, 0.81 MB)

A new use for a clinically validated anti-inflammatory compound (and derivatives thereof) in treatments for rare/ultra-rare orphan skin indications specifically associated with lipid dysfunction e.g. Harlequin Ichthyosis.


↑ Back to top

Reproductive and Regenerative Medicine


diagram

Ectopic pregnancy treatment
(PDF, 0.12 MB)

Ectopic pregnancies can be resolved safely using a method that requires no invasive surgery. The system utilises a combination of methotrexate and orally administered Gefitinib (EGFR inhibition).


diagram

MOGRIFYTM – Direct reprogramming between all human cell types
(PDF, 0.37 MB)

A new algorithm that can identify the minimal transcription factor (TF) combinations required to reprogram one somatic human cell type into another, without the need for first reprogramming cells to a primitive or pluripotent fate.


diagram

Skeletal muscle precursors: Cell differentiation and isolation method
(PDF, 0.27 MB)

A method using specific small-molecule inhibitors and growth factors to derive skeletal muscle precursor cells from hPSCs. These cells provide a valuable in vitro and in vivo research tool for studying early human development and disease.


↑ Back to top

Animal health


diagram

Animal health: Single-dose vaccine steriliant
(PDF, 0.18 MB)

A vaccine that, when administered during infancy, could render both sexes of companion animals (dogs and cats) sterile. The approach offers a nonsurgical, single-dose treatment for the permanent and safe sterilisation.